期刊
CLINICAL BREAST CANCER
卷 21, 期 5, 页码 E575-E583出版社
CIG MEDIA GROUP, LP
DOI: 10.1016/j.clbc.2021.02.001
关键词
Diarrhea; Metastatic; Breast cancer; Neratinib; HER2
类别
资金
- Puma Biotechnology, Inc.
Neratinib is an effective treatment for HER2-positive breast cancer, but its primary tolerability concern is diarrhea, which may lead to patients discontinuing the medication if severe.
Neratinib is an irreversible, pan-human epidermal growth factor inhibitor that has shown efficacy across human epidermal growth factor receptor 2 (HER2)-positive breast cancer settings. Neratinib is indicated for use as extended adjuvant therapy for HER2-positive early-stage breast cancer or, in combination with capecitabine, in the treatment of HER2-positive metastatic breast cancer. The primary tolerability concern with neratinib is diarrhea, and severe diarrhea early in treatment can lead to a substantial proportion of patients discontinuing neratinib, which may lead to reduced or nonexistent efficacy. In order to establish a set of treatment recommendations for use of neratinib, on May 12, 2020, an expert panel of oncologists and gastroenterologists met virtually to discuss the role of neratinib in the treatment of patients with HER2-positive breast cancer. The panel reviewed the current data on neratinib, including efficacy across settings and diarrhea management strategies. Based on these data and their clinical experience, the panelists developed a set of recommendations to guide selection of patients for neratinib, implement weekly dose escalation at initiation of therapy, and prophylactically manage diarrhea.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据